Figure 5.

GW627368X interferes with EP4/EGFR interactive signaling in cervical cancer. (a–d) Cervical cancer cells were treated with 9, 10 and 10 μM of drug for HeLa, SiHa and ME 180, respectively, followed by stimulation with 25 ng/ml of recombinant EGF for 30 min and equal amount of proteins (50 μg) were analyzed by western blotting. (a) Representative blots showing western blot analysis of key proteins. (b–d) Relative levels of phosphorylation of each protein was determined by densitometry. Data presented as mean±S.D., P<0.05, **P<0.01, ***P<0.001 of three independent experiments performed in triplicates. (e) Cells were treated with one third of IC₅₀(48 h) of the drug, incubated for different time periods and protein was extracted from whole cell, nuclear and cytoplasmic fractions and relative β-catenin expression in equal amount of protein (50 μg) was analyzed by western blot. (f and g) The relative levels of protein expression was determined by densitometry. Data presented as mean±S.D., P<0.05, **P<0.01, ***P<0.001 of three independent experiments performed in triplicates